10 results
10-K
2023 FY
SLRN
Acelyrin Inc
28 Mar 24
Annual report
4:21pm
to be a number of legislative initiatives and enforcement interest to contain healthcare costs, increase transparency in drug pricing, and amend specialty … product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk
8-K
EX-99.1
SLRN
Acelyrin Inc
27 Nov 23
ACELYRIN, INC. Provides Update on Izokibep Clinical Development Program
4:31pm
and hidradenitis suppurativa,” said Shao-Lee Lin, MD, PhD, founder and CEO of ACELYRIN. “However, we are a company founded on truth and transparency, and we
10-Q
8vu5tirt
15 Jun 23
Quarterly report
4:19pm
424B4
fco9fxqf1mkiflfv59
5 May 23
Prospectus supplement with pricing info
4:22pm
S-1/A
jlvmz464
1 May 23
IPO registration (amended)
6:10am
S-1
0r1a8z anht05
13 Apr 23
IPO registration
5:10pm
- Prev
- 1
- Next